Recursion Pharmaceuticals, Inc.
HealthcareNASDAQ:RXRX · NASDAQ Global Select
+$0.00 today
Vol 14.75M · Avg 15.44M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-57.0%
avg -23.4%
ROIC
-48.1%
avg -45.0%
ROA
-43.7%
avg -40.2%
Analysis
ROA is currently the strongest return metric at -43.7% versus its period average of -40.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Christopher C. Gibson | Co-Founder, Chairman & Interim Executive Advisor | $952,508.00 | — | 43 | $923,735.00 | 0.21% |
Najat Khan | CEO, President & Director | $903,460.00 | — | 42 | $2.18M | 0.49% |
Vicki L. Goodman | Chief Medical Officer | $793,399.00 | — | 55 | — | — |
David J. Mauro | Advisor | $793,399.00 | — | 61 | $1.07M | 0.24% |
Ben R. Taylor | Chief Financial Officer & President of Recursion UK | $751,492.00 | — | 49 | $1.11M | 0.25% |
Sid Jain | Senior Vice President of Clinical Development & Data Science | — | — | — | — | — |
Erica Fox | Chief People and Impact Officer | — | — | — | — | — |
Kristen Rushton | Chief Operating Officer | — | — | — | — | — |
David Hallett | Chief Scientific Officer | — | — | 57 | $1.07M | 0.24% |
Elizabeth Bruckheimer | Vice President of Clinical Development | — | — | — | — | — |
Ryan Kelly | Chief Communications Officer | — | — | — | — | — |
Benjamin Mabey | Chief Technology Officer | — | — | 43 | — | — |
Matthew Kinn | Chief Business Officer | — | — | — | — | — |
Nathan Hatfield | Chief Legal Officer & Corporate Secretary | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
36
$12.38M
Net Sentiment
$12.38M
Net selling
Most Active
Gibson Christopher
21 transactions
1–10 of 36
Analysis
Insiders reported 0 buys worth $0.00 and 36 sells worth $12.38M over the last 12 months. That adds up to net selling of $12.38M. Gibson Christopher was the most active insider with 21 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +134.3% | +33.4% (6yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +134.3% over three years. Forward estimates point to Revenue at +33.4% (6yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
ImmunityBio, Inc.
NASDAQ:IBRX
$7.44B
Liquidia Corporation
NASDAQ:LQDA
$6.33B
Cogent Biosciences, Inc.
NASDAQ:COGT
$5.66B
Denali Therapeutics Inc.
NASDAQ:DNLI
$3.44B
Beam Therapeutics Inc.
NASDAQ:BEAM
$2.99B
Arcus Biosciences, Inc.
NYSE:RCUS
$2.40B
89bio, Inc.
ETNB
$2.20B
Galapagos N.V.
GLPG
$1.84B
Agios Pharmaceuticals, Inc.
NASDAQ:AGIO
$1.75B
Sarepta Therapeutics, Inc.
NASDAQ:SRPT
$1.62B
Who manages RXRX?
Recursion Pharmaceuticals, Inc. (RXRX) lists 14 active executives. The top listed executive is Vicki L. Goodman, Chief Medical Officer.
Are RXRX insiders buying or selling?
Recent insider activity shows net buying of $2.24M.
Explore More
Continue the stock analysis
Jump to another research area for this company.